1	Detection of SARS-CoV-2 in saliva using tailed amplicon sequencing
2	Aaron Garoutte ¹ , Tasha M. Santiago-Rodriguez ¹ , Heather L. Fehling ² , Rafal Iwasiow ^{3,*}
3	¹ Diversigen, Inc., Houston, TX, USA, 77046; ² Clinical Reference Laboratory, Inc. Lenexa, KS
4	66215; ³ DNA Genotek, Inc., Ottawa, Ontario, CA, K2V 1C2
5	
6	ABSTRACT

7 The most recent virus from the *Coronaviridae* family infecting humans, SARS-CoV-2, has 8 resulted in a global pandemic. As part of the surveillance efforts, SARS-CoV-2 genomes are 9 increasingly being made publicly available. Methods that include both short- and long-read 10 sequencing have been used to elucidate SARS-CoV-2 genomes; however, many of these 11 untargeted approaches may require deeper sequencing for greater genome coverage. For this 12 reason, sequence capture or amplicon-based approaches for SARS-CoV-2 genome sequencing 13 have been developed. The present study evaluated a modified sequence capture approach, 14 namely, tailed amplicon sequencing, to determine SARS-CoV-2 near complete genome 15 sequences from the saliva of infected individuals. Particularly, the suitability of saliva samples 16 stored at room temperature using OMNIgene®•ORAL OME-505 was evaluated. The tailed 17 amplicon sequencing approach poses the additional advantage of being a cost-effective method 18 for library preparation. Different known SARS-CoV-2 variants were identified across the 19 infected subjects, with an average of > 99.4% genome coverage. This methodology also enabled 20 robust genomic surveillance using phylogenetic analyses. The present study supports the 21 suitability of saliva stored at room temperature using collection devices for SARS-CoV-2 variant 22 detection. Importantly, the present study supports the use of tailed amplicon sequencing

23	approaches as an alternative, cost-effective method for SARS-CoV-2 detection in saliva for
24	genomic surveillance.
25	
26	Keywords: genomic surveillance; SARS-CoV-2; sequence capture; tailed amplicon sequencing
27	
28	*Corresponding author email: rafal.iwasiow@dnagenotek.com
29	
30	INTRODUCTION

31 Human saliva is home to over 700 microbial species, and serves as protection against 32 bacterial, fungal and viral infections that could potentially reach the respiratory tract (Kilian et 33 al., 2016). It is composed of water and the secretion of salivary glands, dental plaque, as well as 34 nasal and bronchial secretions; thus, several different viruses in human saliva can be identified, 35 some of which may cause disease. The interactions with viruses and specific saliva components 36 can be virus-specific, complex and can potentially influence their detection as a result of the 37 biological functions of saliva (Y. Li et al., 2020). Viruses including, but not limited to hepatitis A 38 (Leon et al., 2015), hepatitis B (Khadse et al., 2016; Parizad et al., 2016), cytomegalovirus (De Carvalho Cardoso et al., 2015), Epstein Barr virus (Kwok et al., 2015), Zika virus (Bonaldo et 39 40 al., 2016), and Severe Acute Respiratory Syndrome-Associated coronavirus (SARS-CoV) (Wang 41 et al., 2004), have all been detected in the saliva of infected individuals. This has prompted the 42 investigation of saliva as a potential sample type for the diagnosis of several of the mentioned 43 viruses, and of potential emerging and re-emerging viral pathogens.

44 The most recent virus from the *Coronaviridae* family known to infect humans, SARS45 CoV-2 has also been identified in the saliva of infected individuals (Y. Li et al., 2020). While the

46	origin of SARS-CoV-2 is a subject of ongoing research and speculation, it shares 96% identity
47	with a bat coronavirus (Zhou et al., 2020), 90% with coronaviruses present in pangolins (Zhang
48	et al., 2020), and 80% with SARS-CoV (Zhou et al., 2020). SARS-CoV-2 is known to also be
49	transmitted through aerosol droplets, which may also include salivary droplets. Several studies
50	have identified SARS-CoV-2 in saliva (Han and Ivanovski, 2020; Y. Li et al., 2020), and have
51	proposed its use as an alternative to nasopharyngeal (NP) and oropharyngeal (OP) sample
52	collection, which pose additional discomfort and the need for trained personnel (Yoon et al.,
53	2020). In addition, with the availability of at-home collection kits, subjects are more willing to
54	self-collect saliva(Valentine-Graves et al., 2020). Supervised, self-collected saliva has shown to
55	perform similarly to clinician-collected NP swabs for the detection of SARS-CoV-2 in terms of
56	virus detection and quantification (Noah et al., 2020). Success of detection methods for SARS-
57	CoV-2 depends, among many things, on the persistence and inactivation of the virus and nucleic
58	acids. For example, SARS-CoV-2 is detectable using reverse transcription PCR (RT-PCR) for an
59	average of 18 to 20 days, and up 21 to 26 days in some instances (To et al., 2020; Yoon et al.,
60	2020). Saliva has also been suitable for antibody testing, showing that SARS-CoV-2 antibodies
61	can be detected as early as 10 days (To et al., 2020). This further supports the use of saliva for
62	the detection of SARS-CoV-2 nucleic acids and antibodies. Other factors affecting SARS-CoV-2
63	detection include efficient viral lysis, with various commercially available kits and methods
64	showing varying levels of efficiency (Chu et al., 2020).
65	The gold standard for the detection of SARS-CoV-2 in any sample type is RT-PCR or
66	quantitative RT-PCR (RT-qPCR) (Takeuchi et al., 2020). As with any PCR-based method,
67	success will depend on primer specificity; thus, the RNA target genome(s) sequence(s) should be
68	known in order to increase sensitivity (D. Li et al., 2020). Other, less evaluated methods for the

69 detection and surveillance of SARS-CoV-2 in various sample types include high-throughput 70 sequencing. RNA high-throughput sequencing was originally used in combination with other 71 methods to identify the novel coronavirus in subjects suffering from pneumonia of unknown 72 origin, showing a similarity close to 90% to coronaviruses present in bats(Wu et al., 2020). High-73 throughput sequencing can continue to be used for the surveillance of known and novel SARS-74 CoV-2 variants, and also to determine genetic diversity, which is usually not provided by RT-75 PCR or RT-qPCR (Pérez Cataluña et al., 2021). Two approaches have been developed for the 76 detection of SARS-CoV-2 in various sample types using high-throughput sequencing, namely, 77 untargeted and amplicon-based. Untargeted high-throughput sequencing provides the advantage 78 of detecting and monitoring both known and emerging SARS-CoV-2 variants, with the caveat of 79 requiring deeper sequencing to obtain the needed genome coverage for identification, making 80 this approach relatively more cost-prohibiting. Amplicon high-throughput sequencing, or 81 sequence capture methods, have been more widely applied for the detection of SARS-CoV-2 as 82 it represents a more cost-effective approach. One caveat of sequence capture approaches is the 83 failure to cover the entire viral genome as the primers usually cannot cover the genomic ends 84 (Gohl et al., 2020).

Approaches, such as the ARTIC network, have developed methods for amplicon pool preparation for the sequencing of SARS-CoV-2 which involve a 'lab-in-a-suitcase' that can be used in remote and resource-limited areas (<u>https://artic.network/1-about.html</u>). In the ARTIC network protocol, the first cDNA strand is enriched by amplifying with two different pools of primers. This generates amplicons tiling the virus genome, which are then subjected to either Illumina or Oxford Nanopore library preparation and sequencing. More recently, a modification to the ARTIC network protocol, known as tailed amplicon sequencing, has been developed to

92	reduce library preparation cost and time (Gohl et al., 2020). The method has been shown to
93	achieve results comparable to the ARTIC network protocol (Gohl et al., 2020). Briefly, in the
94	tailed amplicon approach, the first cDNA strand is enriched using the ARTIC v3 primers. In this
95	case, the primers also contain adapter tails that allow sequencing libraries to be created through a
96	second indexing PCR. This, in turn, adds sample-specific barcodes and flow cell adapters.
97	Notably, this modification to the ARTIC protocol has not been extensively tested in saliva
98	samples. Therefore, the main aim of the present study was to evaluate the suitability of the
99	modified tailed amplicon sequencing protocol for the detection of SARS-CoV-2 and its ability to
100	discern potential variants in human saliva.
101	
102	MATERIALS AND METHODS
103	Sample collection and RNA extraction
104	Saliva samples were collected from various geographical locations in United States using
105	the OMNIgene®•ORAL OME-505 device (DNA Genotek, Inc) and shipped to Clinical
106	
107	Reference Laboratory, Inc. for testing using the CRL Rapid Response TM COVID-19 Test. After
	testing, the remaining saliva samples collected and stabilized in the OMNIgene®•ORAL OME-
108	Reference Laboratory, Inc. for testing using the CRL Rapid Response TM COVID-19 Test. After testing, the remaining saliva samples collected and stabilized in the OMNIgene®•ORAL OME- 505 devices, were stored at room temperature for up to 15 days prior to RNA extraction (Table
108 109	 Reference Laboratory, Inc. for testing using the CRL Rapid ResponseTM COVID-19 Test. After testing, the remaining saliva samples collected and stabilized in the OMNIgene®•ORAL OME-505 devices, were stored at room temperature for up to 15 days prior to RNA extraction (Table 1). At a later point, one to fifteen days post diagnosis, eight randomly selected samples from a
108 109 110	Reference Laboratory, Inc. for testing using the CRL Rapid Response TM COVID-19 Test. After testing, the remaining saliva samples collected and stabilized in the OMNIgene®•ORAL OME- 505 devices, were stored at room temperature for up to 15 days prior to RNA extraction (Table 1). At a later point, one to fifteen days post diagnosis, eight randomly selected samples from a pool of samples which had previously tested positive for SARS-CoV-2 by the CRL Rapid
108 109 110 111	Reference Laboratory, Inc. for testing using the CRL Rapid Response™ COVID-19 Test. After testing, the remaining saliva samples collected and stabilized in the OMNIgene®•ORAL OME- 505 devices, were stored at room temperature for up to 15 days prior to RNA extraction (Table 1). At a later point, one to fifteen days post diagnosis, eight randomly selected samples from a pool of samples which had previously tested positive for SARS-CoV-2 by the CRL Rapid Response [™] COVID-19 Test were selected to be sequenced. The only criteria used for sample
108 109 110 111 112	Reference Laboratory, Inc. for testing using the CRL Rapid Response TM COVID-19 Test. After testing, the remaining saliva samples collected and stabilized in the OMNIgene®•ORAL OME- 505 devices, were stored at room temperature for up to 15 days prior to RNA extraction (Table 1). At a later point, one to fifteen days post diagnosis, eight randomly selected samples from a pool of samples which had previously tested positive for SARS-CoV-2 by the CRL Rapid Response TM COVID-19 Test were selected to be sequenced. The only criteria used for sample selection was an initial Ct value <30 (Table 1). The randomly selected samples were extracted
108 109 110 111 112 113	Reference Laboratory, Inc. for testing using the CRL Rapid Response TM COVID-19 Test. After testing, the remaining saliva samples collected and stabilized in the OMNIgene®•ORAL OME- 505 devices, were stored at room temperature for up to 15 days prior to RNA extraction (Table 1). At a later point, one to fifteen days post diagnosis, eight randomly selected samples from a pool of samples which had previously tested positive for SARS-CoV-2 by the CRL Rapid Response TM COVID-19 Test were selected to be sequenced. The only criteria used for sample selection was an initial Ct value <30 (Table 1). The randomly selected samples were extracted using the Zymo Quick RNA/DNA Viral MagBead kit (Cat. No. R2141) following

115

116 Sample processing, sequencing and bioinformatic analyses

117 The extracted RNA was then prepared and sequenced using previously described 118 methods in Gohl et al., 2020 (Gohl et al., 2020). Briefly, the integrity of the extracted RNA was 119 analyzed as described previously. After RNA quality and integrity was checked, RT-qPCR was 120 also performed as described previously. RNA was also processed through the amplicon-based 121 sequencing method that utilizes adapter tails with the ARTIC network v3 primers, allowing for a 122 more efficient library preparation (Itokawa et al., 2020). Sequencing was also performed as 123 previously described using a MiSeq $600 \Box$ cycle v3 kit following manufacturer's instructions. 124 After sequencing, the paired ends were joined using PANDAseq (Masella et al., 2012). 125 Unaligned reads were aligned to Wuhan-Hu-1 SARS-CoV-2 genome (MN908947.3) using BWA 126 (Li and Durbin, 2010; Wu et al., 2020). The Ivar software package was used for trimming and 127 filtering reads (Grubaugh et al., 2019). Ivar was also used to call variants and generate consensus 128 sequences. The consensus sequences were then strain typed using Pangolin (github.com/cov-129 lineages/pangolin). Genome coverage plots were created using custom R scripts. Phylogenetic 130 tree was created using the Nextstrain web interface (Hadfield et al., 2018)(v0.14.2, commit: 131 f62d906, build 655).

132

133 **RESULTS AND DISCUSSION**

The present study evaluated a modified sequence capture approach, namely tailed
amplicon sequencing, for the detection of SARS-CoV-2 in the saliva of infected individuals [21].
Detection of SARS-CoV-2 in the saliva of infected individuals, both symptomatic and
asymptomatic, has expanded the toolbox of methods for the detection and diagnostics of the

138	virus. While RT-PCR and RT-qPCR are the standard methods for the detection of SARS-CoV-2
139	in various sample types, tailed amplicon sequencing approaches are also capable of identifying
140	SARS-CoV-2 in the saliva of infected individuals. Notably, results from the present study
141	showed that the tailed amplicon sequencing approach was successful in the identification of
142	various SARS-CoV-2 variants in human saliva (Table 1). Results also showed the suitability of
143	OMNIgene®•ORAL OME-505 for sufficient SARS-CoV-2 RNA recovery for tailed amplicon
144	sequencing. Moreover, storage of saliva samples at room temperature using OMNIgene®•ORAL
145	OME-505 for up to 15 days further supports the capacity of this collection device to capture
146	saliva composition at the time of collection, essential for SARS-CoV-2 diagnostics and
147	surveillance. While upper and lower respiratory tract specimens were first to be recommended
148	for SARS-CoV-2 diagnosis, saliva has gained acceptance as a suitable, non-invasive sample
149	type. Indeed, saliva has been included in numerous FDA Emergency Use Authorizations for the
150	purpose of SARS-CoV-2 diagnosis, including CRL Rapid Response TM . The OMNIgene®•ORAL
151	OME-505 saliva collection device, which has received EUA for SARS-CoV-2 sample collection,
152	allows for self-collection and to circumvent the need to store samples on ice or frozen.
153	
154	Table 1. Summary of relevant metadata associated with saliva samples including: Pangolin
155	lineage which indicates the strain identity, Nexclade clade identification which shows the
156	phylogenetic lineage of the variant, qPCR Ct value for diagnosis, number of raw fastq reads, read
157	depth on the genome after trimming primers, percent coverage of the genome after trimming and
158	the number of variants (mutations) identified using iVar.
159	

Saliva	Pangolin	Nextclade	Collection	Diagnosis	Days	Fastqc	Depth	Coverage	ivar num
--------	----------	-----------	------------	-----------	------	--------	-------	----------	----------

sample ID	Lineage	Clade	Location	Ct value	from sample collection to RNA extraction	Raw Read Pairs	after trimming	(%) After Trimming	variants identified
А	B.1.2	20G	Belton, MO	27.01	15	192151	2316.21	99.96	18
В	B.1	20C	Wilmington, DE	14.01	12	260188	2413.47	99.44	21
С	B.1.2	20G	Bronx, NY	16.50	3	233789	2547.39	99.73	29
D	B.1.1.222	20B	Blacklick, OH	17.40	7	137894	1571.84	99.96	29
Е	P.2	20B	Orient, OH	17.64	11	166102	2166.38	99.76	27
F	B.1.427	20C	Manhattan, KS	17.90	4	135078	1527.50	99.91	30
G	B.1.2	20G	Carson, CA	18.28	2	212666	2146.30	99.81	22
Н	B.1.1.7	20I/501Y.V1	Topeka, KS	18.55	7	202621	2527.93	99.83	39

161

162 Interestingly, the tailed amplicon sequencing approach tested in the present study 163 provided near complete genomes (>99.4 % average genome coverage) for all eight samples 164 tested (**Table 1** and **Figure 1**). In addition, the tailed amplicon method produced a relatively 165 uneven genome coverage balance. Indeed, this has been noted previously when comparing the 166 tailed amplicon method with the ARTIC network protocol (Gohl et al., 2020). One feasible 167 explanation for this unevenness in genome coverage is the better balance of the untailed primers 168 utilized in the ARTIC network protocol. Nevertheless, near complete SARS-CoV-2 genomes 169 were obtained in the present study, which may improve insights into virus mutations, evolution, 170 and adaptation (e.g., increased transmissibility and infectivity) compared to evolutionary 171 relationships across spike protein sequences alone. Unlike specific genes, complete or near 172 complete genomic sequences provide the most high-resolution information that allows 173 determination of variant and strain relatedness during outbreaks and pandemics. Thus, the development of cost-effective and less time-consuming protocols to determine genomic 174 175 sequences is of importance. In addition, near complete genome information may also aid in the 176 classification of SARS-CoV-2 variants into strains. SARS-CoV-2 strain level resolution using 177 tailed amplicon sequencing approaches could potentially aid to bridge mutations within SARS-

- 178 CoV-2 genomes at a global scale, which in turn may aid to understand virus transmission and
- 179 population dynamics. Variant level resolution of SARS-CoV-2 may also facilitate the
- 180 identification of novel target regions for vaccine development and therapeutics, particularly
- regions across SARS-CoV-2 genomes that may be shared across variants and potential strains.



SARS-CoV-2 (Sample A) Genome Coverage

182

Figure 1. Representative example of SARS-CoV-2 genome coverage. Graph illustrates that the combination of sample collection and sequencing methodology is sensitive enough to capture most of the genome with very high coverage.

186

187 Near complete genomic sequences obtained using the tailed amplicon sequencing enabled 188 deciphering phylogenetic relationships across the various SARS-CoV-2 variants identified in the 189 saliva of the infected individuals in comparison with known clades (**Figure 2**). Results show 190 that, overall, the tailed amplicon method described above is sensitive enough to resolve, not only 191 large-scale genomic differences across different clades, but also differences within clades.

- 192 Phylogenetic relatedness may further contribute to the understanding of the pathogenic dynamics
- 193 of SARS-CoV-2 and associated strains over time and link these genetic variations to specific
- 194 geographical regions, which in turn can target genomic surveillance efforts.
- 195







- 199 scale genomic differences across different clades, but also differences within clades.
- 200
- 201
- 202
- 203 CONCLUSIONS

204	The present study evaluated tailed amplicon sequencing as a suitable approach for the
205	detection of SARS-CoV-2 variants in the saliva of infected individuals collected using
206	OMNIgene®•ORAL OME-505. Near complete genome sequences were obtained using the
207	evaluated method, which in turn facilitated phylogenetic analysis with various SARS-CoV-2
208	variants. Near complete or complete genome sequences from SARS-CoV-2 variants continue to
209	be invaluable in disease control and prevention efforts during the COVID-19 pandemic; thus, the
210	evaluation of time- and cost-effective methods such as tailed amplicon sequencing is essential.
211	
212	Author contributions
213	AG-data analysis, figure generation and manuscript draft editing. TSR-writing and editing of
214	original manuscript draft. HLF-sample collection and screening for positive samples RI-
215	conceptualization, and manuscript draft editing.
216	
217	Acknowledgements
218	We thank Mike Tayeb, Geoffrey M. Graham and Austin Udocor for reviewing the manuscript
219	draft.
220	
221	Funding
222	No funding was received for this study.
223	
224	Informed Consent and Release Statement
225	Written informed consent and release statement has been obtained from the patient(s) to publish
226	this paper.

227

228 Institutional Review Board Statement

- 229 The study is exempt under 45 CFR § 46.104(d)(4), because the research involves the use of
- 230 identifiable private information/biospecimens; and information, which may include information
- about biospecimens, is recorded by the investigator in such a manner that the identity of the
- human subjects cannot readily by ascertained directly or through identifiers linked to the
- subjects, the investigator does not contact the subjects, and the investigator will not re-identify
- subjects.
- 235

236 **Conflict of interest**

- AG and TSR are current employees of Diversigen Inc. RI is a current employee of DNA
- 238 Genotek.
- 239

240 Data availability

- 241 SARS-CoV-2 sequence genomes are available on the Global Initiative on Sharing Avian
- 242 Influenza Data (GISAID) site under IDs EPI_ISL_2156824, EPI_ISL_2156826,
- 243 EPI_ISL_2156827, EPI_ISL_2156821, EPI_ISL_2156810, EPI_ISL_2156811,
- 244 EPI_ISL_2156823, EPI_ISL_2156808.
- 245

246 **References**

- 247 Bonaldo MC, Ribeiro IP, Lima NS, dos Santos AAC, Menezes LSR, da Cruz SOD, et al.
- 248 Isolation of Infective Zika Virus from Urine and Saliva of Patients in Brazil. PLoS Negl Trop
- 249 Dis 2016. https://doi.org/10.1371/journal.pntd.0004816.

- 250 De Carvalho Cardoso ES, De Santos Jesus BL, da Silva Gomes LG, Sousa SMB, Gadelha SR,
- 251 Marin LJ. The use of saliva as a practical and feasible alternative to urine in large-scale
- 252 screening for congenital cytomegalovirus infection increases inclusion and detection rates. Rev
- 253 Soc Bras Med Trop 2015. https://doi.org/10.1590/0037-8682-0200-2014.
- 254 Chu AWH, Chan WM, Ip JD, Yip CCY, Chan JFW, Yuen KY, et al. Evaluation of simple
- 255 nucleic acid extraction methods for the detection of SARS-CoV-2 in nasopharyngeal and saliva
- 256 specimens during global shortage of extraction kits. J Clin Virol 2020.
- 257 https://doi.org/10.1016/j.jcv.2020.104519.
- 258 Gohl DM, Garbe J, Grady P, Daniel J, Watson RHB, Auch B, et al. A rapid, cost-effective tailed
- amplicon method for sequencing SARS-CoV-2. BMC Genomics 2020.
- 260 https://doi.org/10.1186/s12864-020-07283-6.
- 261 Grubaugh ND, Gangavarapu K, Quick J, Matteson NL, De Jesus JG, Main BJ, et al. An
- amplicon-based sequencing framework for accurately measuring intrahost virus diversity using
- 263 PrimalSeq and iVar. Genome Biol 2019. https://doi.org/10.1186/s13059-018-1618-7.
- 264 Hadfield J, Megill C, Bell SM, Huddleston J, Potter B, Callender C, et al. NextStrain: Real-time
- tracking of pathogen evolution. Bioinformatics 2018.
- 266 https://doi.org/10.1093/bioinformatics/bty407.
- 267 Han P, Ivanovski S. Saliva-friend and foe in the COVID-19 outbreak. Diagnostics 2020.
- 268 https://doi.org/10.3390/diagnostics10050290.
- 269 Itokawa K, Sekizuka T, Hashino M, Tanaka R, Kuroda M. A proposal of alternative primers for
- the ARTIC Network's multiplex PCR to improve coverage of SARS-CoV-2 genome sequencing.
- 271 BioRxiv 2020.
- 272 Khadse S V., Bajaj G, Vibhakar P, Nainani P, Ahuja R, Deep G. Evaluation of specificity and

- sensitivity of oral fluid for diagnosis of hepatitis B. J Clin Diagnostic Res 2016.
- 274 https://doi.org/10.7860/JCDR/2016/17319.7107.
- 275 Kilian M, Chapple ILC, Hannig M, Marsh PD, Meuric V, Pedersen AML, et al. The oral
- 276 microbiome An update for oral healthcare professionals. Br Dent J 2016.
- 277 https://doi.org/10.1038/sj.bdj.2016.865.
- 278 Kwok H, Chan KW, Chan KH, Chiang AKS. Distribution, persistence and interchange of
- 279 epstein-barr virus strains among PBMC, plasma and saliva of primary infection subjects. PLoS
- 280 One 2015. https://doi.org/10.1371/journal.pone.0120710.
- Leon LAA, De Almeida AJ, De Paula VS, Tourinho RS, Villela DAM, Gaspar AMC, et al.
- 282 Longitudinal Study of Hepatitis A Infection by Saliva Sampling: The Kinetics of HAV Markers
- in Saliva Revealed the Application of Saliva Tests for Hepatitis A Study. PLoS One 2015.
- 284 https://doi.org/10.1371/journal.pone.0145454.
- Li D, Zhang J, Li J. Primer design for quantitative real-time PCR for the emerging Coronavirus
- 286 SARS-CoV-2. Theranostics 2020. https://doi.org/10.7150/thno.47649.
- Li H, Durbin R. Fast and accurate long-read alignment with Burrows-Wheeler transform.
- Bioinformatics 2010. https://doi.org/10.1093/bioinformatics/btp698.
- Li Y, Ren B, Peng X, Hu T, Li J, Gong T, et al. Saliva is a non-negligible factor in the spread of
- 290 COVID-19. Mol Oral Microbiol 2020. https://doi.org/10.1111/omi.12289.
- 291 Masella AP, Bartram AK, Truszkowski JM, Brown DG, Neufeld JD. PANDAseq: Paired-end
- assembler for illumina sequences. BMC Bioinformatics 2012. https://doi.org/10.1186/1471-
- 293 2105-13-31.
- 294 Noah K, Fred T, Vlad S, Agatha B, Laura D, Siri K, et al. Self-collected oral fluid and nasal
- swabs demonstrate comparable sensitivity to clinician collected nasopharyngeal swabs for

- 296 Covid-19 detection. MedRxiv 2020. https://doi.org/10.1101/2020.04.11.20062372.
- 297 Parizad Elaheh Gholami, Parizad Eskandar Gholami, Khosravi A, Amraei M, Valizadeh A,
- 298 Davoudian A. Comparing HBV viral load in serum, Cerumen, and saliva and correlation with
- HBeAg serum status in patients with chronic hepatitis B infection. Hepat Mon 2016.
- 300 https://doi.org/10.5812/hepatmon.30385.
- 301 Pérez Cataluña A, Chiner-Oms Á, Cuevas Ferrando E, Díaz-Reolid A, Falcó I, Randazzo W, et
- 302 al. Detection Of Genomic Variants Of SARS-CoV-2 Circulating In Wastewater By High-
- 303 Throughput Sequencing 2021.
- 304 Takeuchi Y, Furuchi M, Kamimoto A, Honda K, Matsumura H, Kobayashi R. Saliva-based pcr
- 305 tests for sars-cov-2 detection. J Oral Sci 2020. https://doi.org/10.2334/josnusd.20-0267.
- To KKW, Tsang OTY, Leung WS, Tam AR, Wu TC, Lung DC, et al. Temporal profiles of viral
- 307 load in posterior oropharyngeal saliva samples and serum antibody responses during infection by
- 308 SARS-CoV-2: an observational cohort study. Lancet Infect Dis 2020.
- 309 https://doi.org/10.1016/S1473-3099(20)30196-1.
- 310 Valentine-Graves M, Hall E, Guest JL, Adam E, Valencia R, Shinn K, et al. At-home self-
- 311 collection of saliva, oropharyngeal swabs and dried blood spots for sars-cov-2 diagnosis and
- 312 serology: Postcollection acceptability of specimen collection process and patient confidence in
- 313 specimens. PLoS One 2020. https://doi.org/10.1371/journal.pone.0236775.
- 314 Wang WK, Chen SY, Liu IJ, Chen YC, Chen HL, Yang CF, et al. Detection of SARS-associated
- 315 coronavirus in throat wash and saliva in early diagnosis. Emerg Infect Dis 2004.
- 316 https://doi.org/10.3201/eid1007.031113.
- 317 Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG, et al. A new coronavirus associated with
- human respiratory disease in China. Nature 2020. https://doi.org/10.1038/s41586-020-2008-3.

- 319 Yoon JG, Yoon J, Song JY, Yoon SY, Lim CS, Seong H, et al. Clinical significance of a high
- 320 SARS-CoV-2 viral load in the Saliva. J Korean Med Sci 2020.
- 321 https://doi.org/10.3346/JKMS.2020.35.E195.
- 322 Zhang T, Wu Q, Zhang Z. Probable Pangolin Origin of SARS-CoV-2 Associated with the
- 323 COVID-19 Outbreak. Curr Biol 2020. https://doi.org/10.1016/j.cub.2020.03.022.
- 324 Zhou P, Yang X Lou, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak
- 325 associated with a new coronavirus of probable bat origin. Nature 2020.
- 326 https://doi.org/10.1038/s41586-020-2012-7.